MedPath
HSA Approval

TECHNESCAN HDP FOR INJECTION 3 mg/vial

SIN12151P

TECHNESCAN HDP FOR INJECTION 3 mg/vial

TECHNESCAN HDP FOR INJECTION 3 mg/vial

December 23, 2002

QT INSTRUMENTS (S) PTE LTD

QT INSTRUMENTS (S) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantQT INSTRUMENTS (S) PTE LTD
Licence HolderQT INSTRUMENTS (S) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

**Posology and method of administration** The average activity administered by single intravenous injection is 500 MBq (300 – 700 MBq) in a 50 to 70 kg adult. Other activities may be justifiable. There is no special dosage regimen for the elderly patient. The dose to be administered to a child should be a fraction of the adult dose calculated from the body weight according to the following table. ![Technescan HDP For Injection Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/1abe9641709a3a350b8f1ea131c1c956.png) In very young children (up to 1 year) a minimum dose of 40 MBq is necessary in order to obtain images of sufficient quality. Images obtained shortly after injection (e.g. in the so-called "3-phase bone scan" procedure) will only partly reflect metabolic activity. Late phase static scintigraphy should be performed not earlier than 2 hours after injection. The patient should void before scanning.

INTRAVENOUS

Medical Information

**Therapeutic indications** After reconstitution with Sodium Pertechnetate (99mTc) Injection (Fission or Non-Fission) the agent may be used for bone scintigraphy, where it delineates areas of altered osteogenesis.

**Contra-indications** There are no specific contra-indications.

V09BA01

technetium (99mTc) oxidronic acid

Manufacturer Information

QT INSTRUMENTS (S) PTE LTD

Curium Netherlands B.V.

Active Ingredients

SODIUM OXIDRONATE

3 mg/vial

Oxidronic acid

Documents

Package Inserts

Technescan HDP PI.pdf

Approved: January 11, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TECHNESCAN HDP FOR INJECTION 3 mg/vial - HSA Approval | MedPath